Phillip H. Lam
MedStar Washington Hospital Center
Internal medicineCardiologyIntensive care medicinePropensity score matchingHazard ratioHeart failure with preserved ejection fractionDigoxinHeart failureVentricular assist deviceLower riskOlder patientsIn patientHospitalized patientsAll cause mortalityConfidence intervalMedicineCohortEjection fractionBlood pressure
Publications 79
#1Ezequiel J. Molina (Georgetown University)H-Index: 2
#2S. AhmedH-Index: 1
Last. Samer S. Najjar (Georgetown University)H-Index: 63
view all 11 authors...
BACKGROUND Due to anatomic and physiologic concerns, prior generations of the left ventricular assist devices (LVAD) have frequently been denied to patients with small body size. However, outcomes in patients with small body surface area (BSA) following HeartMate 3 (HM3) LVAD implantation remain relatively unknown. METHODS A cohort of 220 patients implanted at a single center was divided into two groups: BSA ≤1.8 m2 (small BSA, n = 37) and BSA >1.8 m2 (large BSA, n = 183). We investigated baseli...
#1Phillip H. Lam (Veterans Health Administration)H-Index: 10
#2Kalliopi Keramida (GW: George Washington University)
Last. Gaurav Choudhary (Brown University)H-Index: 25
view all 14 authors...
Abstract null null Background null A low right ventricular ejection fraction (RVEF) is a marker of poor outcomes in patients with heart failure with reduced ejection fraction (HFrEF). Beta-blockers improve outcomes in HFrEF, but whether this effect is modified by RVEF is unknown. null null null Methods and Results null Of the 2798 patients in Beta-Blocker Evaluation of Survival Trial (BEST), 2008 had data on baseline RVEF (mean 35%, median 34%). Patients were categorized into an RVEF of less tha...
#1Charles FaselisH-Index: 26
#2Lowell A Safren (Georgetown University)
Last. Farooq H Sheikh (Georgetown University)
view all 12 authors...
Abstract null null Objective null To examine the association between income and cardiovascular disease (CVD) in community-dwelling older adults. null null null Methods null Of the 5795 Medicare-eligible community-dwelling older Americans aged 65–100 years in the Cardiovascular Health Study (CHS), 4518 (78%) were free of baseline CVD, defined as heart failure, acute myocardial infarction, stroke, or peripheral arterial disease. Of them, 1846 (41%) had lower income, defined as a total annual house...
#1Cherinne ArundelH-Index: 8
#2Phillip H. LamH-Index: 10
Last. Ali AhmedH-Index: 64
view all 10 authors...
#1Charles Faselis (USU: Uniformed Services University of the Health Sciences)H-Index: 26
#2Phillip H. Lam (Georgetown University)H-Index: 10
Last. Ali Ahmed (Georgetown University)H-Index: 64
view all 12 authors...
BACKGROUND The effect of loop diuretics on clinical outcomes in heart failure has not been evaluated in randomized controlled trials. In hospitalized patients with heart failure, a discharge loop diuretic prescription has been shown to be associated with improved 30-day outcomes, which appears to be more pronounced in subgroups with congestion. In the current study, we examined these associations and association modifications during longer follow-up. METHODS We assembled a propensity score-match...
#1Hiroto Kitahara (Georgetown University)H-Index: 1
#2Samer S. Najjar (MedStar Washington Hospital Center)H-Index: 63
Last. Ezequiel J. Molina (Georgetown University)H-Index: 2
view all 9 authors...
Iatrogenic chordal rupture with severe mitral regurgitation is a rare but serious complication associated with the use of Impella device. We present a case of a 47-year-old man with ischemic cardiomyopathy who required insertion of an Impella 5.0 device. During Impella support, he developed acute pulmonary edema secondary to newly diagnosed posterior mitral valve chordal rupture and subsequent severe mitral regurgitation. He underwent implantation of a durable left ventricular assist device with...
#1L.M. Peters (MedStar Washington Hospital Center)
#2S. Ahmed (MedStar Washington Hospital Center)H-Index: 1
Last. E.J. Molina (MedStar Washington Hospital Center)H-Index: 3
view all 9 authors...
Purpose To evaluate early hemocompatibility-related outcomes after implementation of a low anti-Xa target heparin protocol following implantation of the HeartMate 3 Left Ventricular Assist Device (LVAD). Methods We reviewed hemocompatibility-related outcomes including mediastinal bleeding, gastrointestinal bleeding (GIB), stroke, and pump thrombosis (PT) events in recipients of HeartMate 3 LVADs before and after implementation of a low anti-Xa target heparin protocol. The higher anti-Xa protocol...
#1Raja Zaghlol (MedStar Washington Hospital Center)H-Index: 4
#2Amre Ghazzal (MedStar Washington Hospital Center)
Last. Samer S. NajjarH-Index: 63
view all 13 authors...
Purpose Continuous infusion of inotropes is increasingly used in patients with end-stage heart failure who are being discharged from the hospital. However, Dobutamine and Milrinone are both known to be arrhythmogenic agents. Because Milrinone does not act through the beta-adrenergic system, it may allow for the cautious addition of beta-blockers (BB). We therefore sought to compare the impact of BB use is these patients on ventricular arrhythmias. Methods We retrospectively reviewed all patients...
#1H. Shah (MedStar Washington Hospital Center)
#2Alexander Papolos (MedStar Washington Hospital Center)H-Index: 7
Last. Christopher Barnett (MedStar Washington Hospital Center)H-Index: 24
view all 14 authors...
Purpose To investigate the safety and efficacy of argatroban in preventing thrombotic complications in patients with suspected heparin-induced thrombocytopenia (HIT) treated with axillary flow left ventricular assist device (Impella). Methods We performed a retrospective observational case-series of patients who were supported on Impella and anticoagulated with argatroban due to suspected HIT. The electronic medical record was reviewed for safety events including hemorrhagic or embolic stroke, b...
#1S. Shadman (University of Maryland Medical System)
#2S. Ahmed (MedStar Washington Hospital Center)H-Index: 1
Last. H. KitaharaH-Index: 1
view all 13 authors...
Purpose Despite the approval of LVADs as destination therapy (DT) nearly 2 decades ago, significant knowledge gaps remain regarding the characteristics and outcomes of AA patients (pts) who receive LVAD therapy as DT. The present analysis sought to assess the characteristics and outcomes of DT LVAD AA pts. Methods Single center retrospective review of DT LVAD pts from 1/1/2009 to 12/31/2019 was performed. We compared clinical characteristics of AAs to non-AAs. Survival and hemocompatibility-rela...